Sandoz Launches Lupin's Ranibizumab Biosimilar in European Markets
Lupin and its commercial partner Sandoz have launched Ranluspec, a biosimilar ranibizumab, across European markets, excluding Germany, following European Commission approval.
Choroidal Vascular Conditions | 12/11/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy